Eurand Announces Launch of OTC Unisom SleepMelts by Chattem

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

MILAN, Italy and DAYTON, Ohio, April 29, 2008 (PRIME NEWSWIRE) --
Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that
develops, manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies, announced today that Chattem, Inc. ("Chattem") has
launched a new orally disintegrating tablet ("ODT") formulation of
its popular over-the-counter (OTC) sleep-aid brand, Unisom(r).

Unisom(r) SleepMelts(tm), which contains 25mg of diphenhydramine
hydrochloride, was developed by Eurand using its AdvaTab(r) and
Microcaps(r) taste-masking technologies. The product was developed as
part of the EUR-1047 program. Unisom(r) SleepMelts(tm), an OTC
sleep-aid, is now available in leading U.S. mass merchandiser, drug
and food retailers. Eurand will exclusively supply the product for
Chattem, which will be manufactured at Eurand's U.S. facility in
Vandalia, OH.

Gearoid Faherty, Chief Executive Officer of Eurand, commented, "We
are pleased to complete the development and witness the launch of our
diphenhydramine ODT product under Chattem's Unisom(r) brand name.
Chattem is a leading marketer of OTC healthcare brands and we are
looking forward to working with them on the successful
commercialization of this product in the U.S. The launch of Unisom(r)
SleepMelts(tm) represents the first product to be commercialized
using our AdvaTab ODT technology and is further evidence of the
strength of our drug formulation technology and development
capabilities."

About AdvaTab(r)

Eurand's AdvaTab(r) technology utilizes proprietary granulation and
tabletting processes to provide an orally disintegrating tablet with
superior mouth-feel attributes. When combined with Eurand's
Microcaps(r) taste-masking technology, AdvaTab ODTs are one of the
leading orally disintegrating tablet systems available to the
pharmaceutical industry today. Key features of AdvaTab include:
excellent mouth-feel; tablets that can be packaged in bottles or
blisters; rapid disintegration in the oral cavity; ability to
incorporate microencapsulated drug particles; and the capacity to
incorporate larger drug doses than conventional ODT technologies.

About Eurand

Eurand is a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies. Eurand has had four partnered products approved by the
FDA since 2001 and has a pipeline of product candidates in
development for itself and its collaboration partners. Eurand has
completed two phase III clinical trials on its lead product
candidate, EUR-1008 (Zentase), intended for the treatment of
pancreatic insufficiency and has submitted an NDA for this product.
Eurand's technology platforms include bioavailability enhancement of
poorly soluble drugs, customized release,
taste-masking/fast-dissolving formulations and drug conjugation.
Eurand is a global company with facilities in the USA and Europe. For
more information, visit Eurand's website at www.eurand.com.

About Chattem

Chattem, Inc. is a leading marketer and manufacturer of a broad
portfolio of branded OTC healthcare products, toiletries and dietary
supplements. The Company's products target niche market segments and
are among the market leaders in their respective categories across
food, drug and mass merchandisers. The Company's portfolio of
products includes well-recognized brands such as Icy Hot, Gold Bond,
Selsun Blue, ACT, Cortizone-10 and Unisom. Chattem conducts a portion
of its global business through subsidiaries in the United Kingdom,
Ireland and Canada. For more information, visit Chattem's website at
www.chattem.com.

This release, and oral statements made with respect to information
contained in this release, constitutes forward-looking statements.
Such forward-looking statements include those which express plan,
anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact
including, but not limited to our plans for our NDA filing,
enrollment and future plans for our clinical trials, progress of and
reports of results from clinical studies, clinical development plans
and product development activities. The words "potentially", "could",
"calls for" and similar expressions also identify forward-looking
statements. These statements are based upon management's current
expectations and are subject to risks and uncertainties, known and
unknown, which could cause actual results and developments to differ
materially from those expressed or implied in such statements.
Factors that could affect actual results include risks associated
with the possibility that the FDA refuses to approve our NDA; the
outcome of any discussions with the FDA; and unexpected delays in
preparation of materials for submission to the FDA as a part of our
NDA filing. Forward-looking statements contained in this press
release are made as of this date, and we undertake no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise. Actual events could
differ materially from those anticipated in the forward-looking
statements.

CONTACT: Eurand N.V.
Mario Crovetto, Chief Financial Officer
+39 02 95428 521
mario.crovetto@eurand.com

The Ruth Group
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com
Elizabeth Scott
646-536-7014
escott@theruthgroup.com

--- End of Message ---

Eurand N.V.
845 Center Drive Vandalia, Ohio USA

WKN: A0MSPK; ISIN:
NL0000886448;
;